{"entity":{"id":"illumina","kind":"company","name":"Illumina","aka":[],"tldr":"Illumina is the dominant DNA sequencing platform underneath nearly every genomic test in oncology.","summary":"Illumina, based in San Diego and listed as ILMN, is the dominant DNA sequencing platform underneath nearly every genomic test in oncology. Its NovaSeq X instruments, the TruSight Oncology 500 panel, approved as an in vitro diagnostic in 2024 to 2025 and carried in OnCo as TruSight Oncology Comprehensive, and a constellation of measurable residual disease and spatial products make it the supplier behind many of the diagnostics companies on this site. OnCo links it to comprehensive genomic profiling and whole-genome sequencing, to new short-read sequencing platforms and clinical bioinformatics, to the CRUK Cambridge Institute, to Illumina Ventures and to the bottleneck that inherited risk is mostly unidentified. Whether new short-read competitors erode its position is the open question. TruSight Oncology Comprehensive has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Illumina,_Inc.","links":[{"label":"Official website","url":"https://www.illumina.com"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics","drug-discovery"],"technologies":["cgp","wes-wgs"],"targets":[],"drugs":[],"companies":["illumina-ventures"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"diagnostics","website":"https://www.illumina.com","ticker":"ILMN","investors":[],"funding":[]},"route":"/companies/illumina/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"ngs-bioinformatics-software","kind":"technology","name":"Clinical NGS bioinformatics and variant interpretation","route":"/technologies/ngs-bioinformatics-software/"},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"next-gen-short-read-platforms","kind":"technology","name":"New short-read sequencing platforms","route":"/technologies/next-gen-short-read-platforms/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"company":[{"id":"illumina-ventures","kind":"company","name":"Illumina Ventures","route":"/companies/illumina-ventures/"}],"bottleneck":[{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/"}],"institution":[{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","route":"/institutions/cruk-cambridge-centre/"}],"drug":[{"id":"trusight-oncology-comprehensive","kind":"drug","name":"TruSight Oncology Comprehensive","route":"/drugs/trusight-oncology-comprehensive/"}]}}